Health & Fitness
Health and Fitness
Health and Fitness
Sun, February 20, 2011Fri, February 18, 2011Thu, February 17, 2011Wed, February 16, 2011Tue, February 15, 2011Mon, February 14, 2011Fri, February 11, 2011Thu, February 10, 2011Wed, February 9, 2011Tue, February 8, 2011Mon, February 7, 2011Sun, February 6, 2011Fri, February 4, 2011Thu, February 3, 2011Wed, February 2, 2011Tue, February 1, 2011Exelixis Announces February 22 Webcast of Its Fourth Quarter & Full Year 2010 Financial Results Conference Call
Published in Health and Fitness on Thursday, February 10th 2011 at 3:22 GMT by Market Wire
SOUTH SAN FRANCISCO, Calif.--([ BUSINESS WIRE ])--Exelixis, Inc. (NASDAQ: EXEL) will release its fourth quarter and full year 2010 financial results on Tuesday, February 22, 2011, after the markets close. The announcement will be followed by a live webcast at 5:00 p.m. EST/ 2:00 p.m. PST. During the webcast, Exelixis management will discuss the companya™s financial results, 2011 financial guidance, corporate strategy, recent clinical data and development plans and priorities for cabozantinib (XL184), and provide a general business update. The webcast may be accessed in the Event Calendar page under Investors at [ http://www.exelixis.com ].
An archived replay of the webcast will be available on the Event Calendar page under Investors at [ http://www.exelixis.com ] and via phone until 11:59 p.m. EST/8:59 p.m. PST on March 22, 2011. Access numbers for the phone replay are: 888-286-8010 (domestic) and 617-801-6888 (international); the passcode is 13557378.
About Exelixis
Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer. The company is leveraging its biological expertise and integrated research and development capabilities to generate a pipeline of development compounds with significant therapeutic and commercial potential for the treatment of cancer. Currently, Exelixis' broad product pipeline includes investigational compounds in phase 3, phase 2, and phase 1 clinical development. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including Bristol-Myers Squibb Company, sanofi-aventis, GlaxoSmithKline, Genentech (a wholly owned member of the Roche Group), Boehringer Ingelheim, and Daiichi-Sankyo for several compounds in its pipeline. For more information, please visit the company's web site at [ www.exelixis.com ].
